Cancer Committee Chair’s Report
highlights just a few of the many leaders and influencers that have invested time and resources to ensure our success. It is also worth noting there are many new, up-and- coming, talented leaders that are similarly dedicated to growth and success of the Cancer Institute. I have been honored to serve as the CCC chair for the last five years and look forward to the great work that Dr. Lloyd, and the entire Cancer Committee, will accomplish.
understanding community needs in our region related to cancer screening, and researching best practices to improve cancer outcomes. She began her career at the Cancer Institute in 2015 and has distinguished herself as a leader in our Cancer Institute and in our region. Dr. Schmocker is a surgical oncologist with a practice focused on laparoscopic and robotic liver and pancreas surgery. Beyond his surgical expertise, he brings a passion for cancer research, improving disparities in cancer care, and improving quality outcomes in all aspects of cancer care. As an organization, we have experienced many talented, diligent, and passionate leaders that have guided the Cancer Institute from its early years to its current stature and regional impact. This article
Jerry Crook, MD, is the Senior Vice President for the Physician Enterprise, which includes almost all of the Cancer Institute physicians. He reports to Keith Gray, MD, MBA, who is the Executive Vice President and Chief Medical Officer. Steve Clapp is the Senior Vice President for Strategic and Business Development. He reports to Joe Landsman, CEO. This talented and inspirational team of leaders are aligned in mission and vision to support the continued growth, innovation, and regional impact of the Cancer Institute. At the level of the Clinical Cancer Committee (CCC), Jill Lloyd, MD, MPH, has been named the new CCC Chair and Ryan Schmocker, MD, FACS, the new Cancer Liaison Physician. Dr. Lloyd is a breast cancer surgeon with a passion for improving access to care,
career as a radiation therapist. She was recruited to the Cancer Institute in 2016 as the Director of Radiation Oncology and the University Breast Center. In June 2022 she was selected as the Executive Director of the Cancer Institute. She brings a broad understanding of delivering high-quality oncology patient care, a strong financial background, and is a gifted communicator. 2022 was also the year that Steve Ross, PhD, announced his retirement as Senior Vice President of Strategic Development. His career at UT Medical Center spanned four decades. He oversaw several important initiatives of the Cancer Institute including facilities expansion and the development of our clinical trials program. Of the many projects Dr. Ross oversaw over his tenure, the key highlights include the elevation of the Cancer Institute to a Center of Excellence (COE) in 1999, developing the Cancer Imaging and Tracer Development program in 2003, the development and designation for the Brain and Spine Institute in 2004, and the development of the Stereotactic Radiosurgery Program in 2005. We are grateful to Dr. Ross for his years of dedicated service. To accommodate our organizational growth, the medical center has divided Dr. Ross’ responsibilities into three leadership categories. Lisa Duncan, MD, is the Senior Vice President for the Centers of Excellence, which includes the Cancer Institute. She reports to James Shamiyeh, MD, who is the Executive Vice President of Clinical Operations.
Cyberknife program, and the development of the Transplant and Cellular Therapy Program. She also was instrumental in developing our hospital-wide Palliative Care Program, creating the Integrative Health Program, overseeing the expansion of oncology services at regional community centers, and was instrumental in the transition of cancer care from paper charting to fully electronic health records. Under her leadership, the Cancer Institute moved from the main hospital to Medical Building D in 2003 and then to its current location in Medical Building F in 2012. As of 2022, the Cancer Institute building is fully dedicated to cancer care including navigation, tumor registry, social work, dietician support, clinical trials, and numerous multidisciplinary tumor board conferences. She had many additional accomplishments including recruiting talented staff and providers, expanding quality standards, and providing necessary services to ensure that almost all aspects of cancer care can be provided here in East Tennessee. Few individuals have had a more lasting impact on the Cancer Institute than Renee. Fortunately, despite her official retirement, she remains active in the Cancer Institute, especially in strategic planning and community expansion. The Cancer Institute was fortunate to identify an excellent and very capable replacement for Renee with the nomination of Susan Stinnett, RT, MBA, as the new Executive Director. Susan has been in health care leadership since 2007. She began her
Sincerely,
James McLoughlin, MD 2022 Clinical Cancer Committee Chair, Surgical Oncologist
Looking back on 2022, The University of Tennessee Cancer Institute again noted increased growth, expanded services, and steady recruitment of providers and staff. 2022 was a year of returning to routines, reengaging regular cancer screening, and expanding access. 2022 was also a year of transitions of leadership. After a career of 23 years as a Cancer Center leader, Renee Hawk retired as Vice President of the Cancer Institute. Renee oversaw and led remarkable growth and a transition of the Cancer Institute from 1999 through 2022. The Cancer Institute was first designated as a Center of Excellence in 1999 at the time that Renee was appointed as Administrative Director. She was then promoted to Vice President of the Cancer Institute in 2005. During her tenure, she oversaw the creation of the University Cancer Specialists and University Gynecologic Oncology practices, the initiation of the
Renee Hawk Vice President, Cancer Institute (retired)
Susan Stinnett, RT, MBA Executive Director, Cancer Institute
Steve Ross, PhD Senior Vice President of Strategic Development (retired)
Steve Clapp Senior Vice President of Strategic Development
Jay Crook MD, JD, FACC Sr. Vice President, Physician Enterprise & Chief Medical Officer
Lisa Duncan, MD Sr. Vice President, Centers of Excellence
Ryan Schmocker, MD Surgical Oncologist, Assistant Professor
Jill Lloyd, MD, MPH Breast Surgeon, Section Chief, Breast Surgical Oncology
4 - Cancer Institute Annual Report 2022
5
Made with FlippingBook - professional solution for displaying marketing and sales documents online